Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Gilead’s remdesivir better suited to mild-to-moderate COVID-19 patients, says GlobalData

Gilead Sciences’ remdesivir is more likely to work in mild-to-moderate COVID-19 patients rather than severe cases, according to reporting from Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda explains: “Given its antiviral mechanism, interviewed experts noted that remdesivir has the potential to decrease viral load in less-severe patients. […]
Read more

Intensive care units would experience severe strain from high-risk groups of COVID-19, says GlobalData

As the COVID-19 situation grows, intensive care units (ICUs) in hospitals have to handle more patients with severe cases of the virus. COVID-19 can be more severe for those individuals with pre-existing conditions such as diabetes, heart disease, chronic obstructive pulmonary disease (COPD), and asthma along with immune-compromised or older individuals. As Europe and the […]
Read more

Risk of severe COVID-19 faced by 330m people in the 9MM, says GlobalData

Coronavirus (COVID-19) has now spread across 184 countries with approximately 1.5 million total confirmed cases worldwide as of 09.04.2020; Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data and analytics company, offers her view on the current challenges facing the 9MM: “We now know that severe and critical forms of COVID-19 are more common in the elderly […]
Read more

COVID-19 leads to unpredictable IPOs and venture financing deals for biopharma companies, says GlobalData

In this unprecedented time of uncertainty, key markets have lost 20–70% of their value year-to-date due to COVID-19, according to GlobalData’s COVID-19 Executive Briefing. Sharon Cartic, Associate Director for Drugs and Business Fundamentals Databases at GlobalData, comments: “This drop in value is inevitably having an impact on the initial public offerings (IPOs) of biopharma companies […]
Read more

Hydroxychloroquine for COVID-19 needs more data

As COVID-19 spreads, the search for a treatment is ramping up. The antimalarial and immunosuppressant hydroxychloroquine has received some attention, including that of President Trump. There are currently around 60 planned or in-progress clinical trials to test its efficacy as a treatment for COVID-19. However, the results of recently completed clinical trials indicate there are not enough data to support hydroxychloroquine use for COVID-19 treatment at the level of expectations […]
Read more

Amgen and Adaptive Biotechnologies join a long list of drug and vaccine development partnerships to combat COVID-19

With the advent of COVID-19 reaching over one million cases worldwide, a concerted effort will be needed to approach this growing problem.  Drug development partnerships between companies that complement their areas of expertise will more rapidly facilitate research on this disease, says GlobalData. Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData, commented: “While past historical data […]
Read more

COVID-19 social distancing measures will impede global RSV clinical development, says GlobalData

Following the introduction of social distancing measures, brought in to reduce the spread of COVID-19 across the globe; Emily Carter-Richardson, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on how this could impact the development of respiratory syncytial virus (RSV) vaccines: “The infection control measures of social distancing to prevent […]
Read more

HCV diagnosed incident cases will substantially increase following updated guidelines

According to new guidelines published by the US Preventive Services Task Force (USPSTF), hepatitis C virus (HCV) screening will now expand to include all adults ages 18 to 79 years, effectively replacing the 2013 recommendations which limited screening to only high-risk individuals and adults born between 1945 and 1965. With the expanded screening criteria, the number of truly diagnosed incident cases will substantially increase over the […]
Read more

Alexion to start Soliris in COVID-19 Phase II trial in next few days, says GlobalData

Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source familiar with the trial told Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda comments: “The source explained that the idea behind Soliris […]
Read more

US COVID-19 cases projected to increase 65% as risk of transmission likely to surpass Italy and Spain, says GlobalData

In the key markets most heavily affected by the coronavirus (COVID-19), case trends are expected to follow a low-risk forecast, with the exception of the US, according to GlobalData, a leading data and analytics company. Natasha Karim, Managing Epidemiologist at GlobalData comments: “Most countries have enforced strict quarantine and mitigation measures. As a result, confirmed […]
Read more

Combination therapies could help overcome limitations of ICIs for oncology indications, says GlobalData

While checkpoint inhibitors as monotherapies have fulfilled expectations in some indications, novel combinations are on the horizon in a broader range of cancers says GlobalData, a leading data and analytics company. The company’s latest report, ‘Immuno-oncology: Focus on Development and Opportunities in Immune Checkpoint Modulators’, reveals that developers are investigating new checkpoint targets to overcome some […]
Read more

COVID-19 pandemic has multitude of implications for cardiovascular and metabolic disorder space, says GlobalData

COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular (CV) and metabolic disorder (CVMD) category. The current uncertainty regarding treatment with certain CV drugs, the supply chain and clinical trials is also notable. Overall, the pandemic is already impacting the CVMD healthcare landscape, and leading data and […]
Read more
1 … 97 98 99 100 101 … 108